- Home
- ZBAI vs ADXN Comparison
ZBAI vs ADXN Comparison
Compare ZBAI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | ADXN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 11.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBAI | ADXN |
|---|---|---|
| Price | $6.66 | $7.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 8.0K |
| Earning Date | 11-13-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,200,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.00 | N/A |
| 52 Week Low | $4.83 | $6.51 |
| 52 Week High | $45.00 | $12.05 |
Technical Indicators
Market Signals| Indicator | ZBAI | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 42.81 |
| Support Level | $6.58 | $7.65 |
| Resistance Level | $6.91 | $8.49 |
| Average True Range (ATR) | 0.25 | 0.57 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 21.98 | 24.86 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.